DCprime’s lead cancer relapse vaccine candidate DCP-001 is generated by transforming a proprietary leukemic cell, DCOne®, into a whole cell-based cancer vaccine. Clinical data from a previously concluded phase 1 clinical study that was presented at the 61st Annual Meeting and Exposition of the American Society of Hematology (ASH) in December 2019 demonstrated DCP-001’s potential to prolong relapse-free survival and overall survival as an allogeneic, off-the-shelf cell-based vaccine in the post-remission setting.
DCP-001 is currently being evaluated in the international, multi-center, open-label proof-of-concept study ADVANCE-II with AML patients in complete remission, but with persistent measurable residual disease (MRD). The associated AML-VACCiN consortium receives support from the EU under the Horizon 2020 program. More information can be found at www.amlvaccin.eu.
